

Arsenic-induced *BRCA1* CpG promoter methylation is associated with the downregulation of ER α and resistance to tamoxifen in MCF7 breast cancer cells and mouse mammary tumor xenografts

ORNELLA I. SELMIN^{1,2}, MICAH G. DONOVAN³, BETHANY SKOVAN¹,
GILLIAN D. PAINE-MURIETA¹ and DONATO F. ROMAGNOLO¹⁻³

¹The University of Arizona Cancer Center; ²Department of Nutritional Sciences;
³Cancer Biology Graduate Interdisciplinary Program, The University of Arizona, Tucson, AZ 85724, USA

Received September 5, 2018; Accepted December 3, 2018

DOI: 10.3892/ijo.2019.4687

Abstract. A significant percentage (~30%) of estrogen receptor- α (ER α)-positive tumors become refractory to endocrine therapies; however, the mechanisms responsible for this resistance remain largely unknown. Chronic exposure to arsenic through foods and contaminated water has been linked to an increased incidence of several tumors and long-term health complications. Preclinical and population studies have indicated that arsenic exposure may interfere with endocrine regulation and increase the risk of breast tumorigenesis. In this study, we examined the effects of sodium arsenite (NaAs^{III}) exposure in ER α -positive breast cancer cells *in vitro* and in mammary tumor xenografts. The results revealed that acute (within 4 days) and long-term (10 days to 7 weeks) *in vitro* exposure to environmentally relevant doses reduced breast cancer 1 (*BRCA1*) and ER α expression associated with the gain of cyclin D1 (*CCND1*) and folate receptor 1 (*FOLR1*),

and the loss of methylenetetrahydrofolate reductase (*MTHFR*) expression. Furthermore, long-term exposure to NaAs^{III} induced the proliferation and compromised the response of MCF7 cells to tamoxifen (TAM). The *in vitro* exposure to NaAs^{III} induced *BRCA1* CpG methylation associated with the increased recruitment of DNA methyltransferase 1 (*DNMT1*) and the loss of RNA polymerase II (*PolII*) at the *BRCA1* gene. Xenografts of NaAs^{III}-preconditioned MCF7 cells (MCF7NaAs^{III}) into the mammary fat pads of nude mice produced a larger tumor volume compared to tumors from control MCF7 cells and were more refractory to TAM in association with the reduced expression of *BRCA1* and ER α , CpG hypermethylation of estrogen receptor 1 (*ESR1*) and *BRCA1*, and the increased expression of *FOLR1*. These cumulative data support the hypothesis that exposure to As^{III} may contribute to reducing the efficacy of endocrine therapy against ER α -positive breast tumors by hampering the expression of ER α and *BRCA1* via CpG methylation, respectively of *ESR1* and *BRCA1*.

Correspondence to: Dr Donato F. Romagnolo, The University of Arizona Cancer Center, The University of Arizona, 1515 North Campbell Avenue, Tucson, AZ 85724, USA
E-mail: donato@u.arizona.edu

Abbreviations: As^{III}, trivalent arsenite; As^V, pentavalent arsenate; *BRCA1*, breast cancer 1; *CCND1*, cyclin D1; ChIP, chromatin immunoprecipitation; DMEM/F12, Dulbecco's modified Eagle's/F12 medium; *DNMT1*, DNA methyltransferase 1; E2, 17 β -estradiol; ER α , estrogen receptor- α ; FCS, fetal calf serum; *FOLR1*, folate receptor 1; *GAPDH*, glyceraldehyde 3-phosphate dehydrogenase; *GEN*, genistein; M, methylated-specific primers; *MTHFR*, methylenetetrahydrofolate reductase; *MTT*, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NaAs^{III}, sodium arsenite; *OVX*, ovariectomized; *PBS*, phosphate-buffered saline; *PolII*, RNA polymerase II; *PR*, progesterone receptor; qPCR, quantitative polymerase chain reaction; TAM, tamoxifen; *TNBC*, triple-negative breast cancers; U, unmethylated-specific primers

Key words: arsenic, estrogen receptor, *BRCA1*, epigenetics, tamoxifen, breast cancer

Introduction

Inorganic arsenic is ubiquitously found in foods (i.e., rice and grains) (1,2) and drinking water (3-5). Chronic arsenic exposure through contaminated water has been linked to an increased incidence of several tumors (6,7) and long-term health complications at levels of exposure below safety limits (10 ppb) (8). Common human exposures to arsenic include inorganic trivalent arsenite (As^{III}) and pentavalent arsenate (As^V). The As^{III} form has potent estrogen-disrupting activities in connection with its affinity for the ligand-binding domain of the estrogen receptor- α (ER α). It also stimulates cell growth and the expression of the progesterone receptor (*PR*) (9). As the As^V form is enzymatically converted to As^{III}, it provides a reservoir for ER α -binding metabolites (10) that may disrupt estrogen signaling and response to endocrine therapies based on antagonists of the ER α (11-13).

Approximately 70-80% of diagnosed breast tumors are ER-positive and they are treated with anti-estrogens, including tamoxifen (TAM). However, over time, a significant percentage (~30%) of these tumors become resistant to treatment with anti-estrogens (14,15). The reasons for this acquired resistance

remain largely unknown. However, the loss of ER α expression has been linked to a poor response to endocrine therapy (16-18). The deregulation of ER α signaling associated with the drinking of water contaminated with arsenic has been reported both in men and women (19). Arsenic-induced genomic instability via the Fanconi anemia (FA)/breast cancer (BRCA) pathway disruption has been shown to directly contribute to arsenic carcinogenic effects (20). A previous study using rodent models (e.g., Sprague-Dawley rats) demonstrated that the *in utero* exposure to As^{III} induced an increase in the number of mammosphere-forming cells, the branching of epithelial cells and density in the mammary gland of prepubertal offspring, and that these changes persisted into adulthood (21). Other studies using rodent models concluded that As^{III} was a 'complete' transplacental carcinogen promoting the maternal dose-dependent induction of tumors in endocrine-related tissues (adrenal gland, ovary and uterus) in offspring (22,23). In a spontaneous mammary-tumor model (C3H/St mice), arsenic exposure was shown to abolish the anticancer effects of selenium and increase tumor growth rates and multiplicity (24). At the cellular level, *in vitro* studies have indicated that chronic exposure to low levels of arsenic induced the transformation of normal breast epithelial cells, and accelerated the growth of ER α -positive breast cancer cells (25,26). Exposure to As^{III} has been shown to inhibit DNA mismatch repair, leading to genomic instability (27,28). In endocrine-responsive tissue (e.g., prostate), exposure to As^{III} has been reported to induce the transition to a steroid receptor-independent tumor phenotype (29). These cumulative observations have raised the question of whether or not endocrine disruption associated with As^{III} exposure contributes to breast carcinogenesis.

Epigenetics refers to changes in DNA methylation, histone post-translational modifications and the expression of non-coding RNAs (30). Maternal exposure to arsenic has been shown to alter DNA methylation in placental tissue (31), and to increase DNA methylation in children (32). Moreover, preclinical (33,34) and human (35) studies have demonstrated that arsenic causes the hypermethylation of tumor suppressor genes (i.e., *p16^{INK4}* and *RASSF1*) and a decrease in telomere length associated with genomic instability (36). Finally, exposure to As^{III} has been found to induce cancer stem cell-like properties involving the epigenetic silencing of the *let-7c* via Ras/NF- κ B pathways (37). Based on these observations, the main objective of this study was to investigate the effects of As^{III} on *BRCA1* and *ESR1* (ER α) expression and CpG methylation, and response to TAM in cultured and xenografted MCF7 breast cancer cells.

Materials and methods

Cells and cell culture. Authenticated breast cancer MCF7 cells (Batch #62349993) were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and maintained at 37°C with 5% CO₂ in Dulbecco's modified Eagle's/F12 medium (DMEM) from Corning Cellgro (Thermo Fisher Scientific, Pittsburgh, PA, USA) supplemented with 10% fetal calf serum (FCS; HyClone Laboratories Inc., Logan UT, USA) as previously described (38). Sodium arsenite (NaAs^{III}), TAM, genistein (GEN) and 17 β -estradiol (E2) were obtained from Sigma-Aldrich (St. Louis, MO,

USA). TAM and E2 were solubilized in stock solutions with ethanol, which was added to DMEM/F12 as the vehicle control. For cell proliferation experiments, the MCF7 cells (passage nos. 3-15) were seeded in 6-well plates at a density of 5x10⁵ cells/well in triplicate overnight, and then switched to phenol-free media containing 10% charcoal-stripped FCS (HyClone Laboratories Inc.) for 3 days before the start of each treatment. For proliferation measurements, the cells were washed with ice-cold PBS and counted by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay (Promega, Madison, WI, USA). This assay is based on the conversion of the yellow tetrazolium dye MTT to purple formazan crystals by metabolically active cells. Briefly, 2x10⁴ cells were seeded in 96-well tissue culture plates and maintained overnight. Six replicates were assigned to each experimental treatment. Following treatment, 15 μ l of MTT dye solution were added to each well, and the plate was incubated for 4 h at 37°C. Solubilization/stop solution (100 μ l) was added for 1 h at room temperature and the absorbance at 570/650 nm was recorded using a Synergy HT plate reader (Bio-Tek Instruments, Winooski, VT, USA). For flow cytometric analysis, trypsinized cells were washed in phosphate-buffered saline (PBS), treated with RNase and stained with propidium iodide (50 μ g/ml). Cell cycle distribution profiles were determined with a FACScan (BD Biosciences, Franklin Lakes, NJ, USA), using a CELLQuest program at the Flow Cytometry Laboratory of the Arizona Cancer Center, and analyzed with MODFIT.2 software.

Promoter CpG methylation. Quantitative polymerase chain reaction (qPCR) analysis of human *BRCA1* and *ESR1* promoter CpG methylation was performed as previously described (38) with genomic DNA (DNeasy blood and tissue kit; Qiagen, Hilden, Germany) and bisulfonated with the Epitect bisulfite kit (Qiagen) using the following unmethylated (U)- and methylated (M)-specific primers (Sigma-Aldrich): *BRCA1* U-sense, 5'-TTGGTTTTTGTGGTAATGGAAAAGTGT-3' and U-antisense, 5'-CAAAAATCTCAACAACTCACACCA-3'; M-sense, 5'-TGGTAACGGAAAAGCG-3' and M-antisense, 5'-ATCTCAACGAACTCACGC-3'; *ESR1* U-sense, 5'-GGATA TGGTTTGTATTTTGTTTTGT-3' and U-antisense, 5'-ACAAA CAATTCAAAAACCTCCAAC-3'; M-sense, 5'-GGTTTT TGAGTTTTTGTTTTG-3' and M-antisense, 5'-AACTTA CTACTATCCAAATACACCTC-3'. The qPCR was carried out in a volume of 10 μ l consisting of the following master mix: 5 μ l of SYBER-Green mix (Thermo Fisher Scientific), 1 μ l each of forward and reverse primers, 2 μ l nuclease-free water, and 1 μ l of bisulfonated genomic DNA. Data from qPCR of bisulfonated DNA were presented as the fold-change compared to the control of the ratio of CpG M/U, as previously described (38).

Chromatin immunoprecipitation assay. The Pierce magnetic chromatin immunoprecipitation (ChIP) kit (Pierce, Rockford, IL, USA) was used to analyze the occupancy of the *BRCA1* promoter by DNA methyltransferase 1 (DNMT1) and RNA polymerase II (PolII) in MCF7 cells according to instructions provided by the manufacturer. Briefly, the cells were fixed in 1% paraformaldehyde for 10 min and neutralized with glycine. After 2 washes with cold PBS and protease inhibitors cocktail, cells were resuspended in membrane extraction buffer and




Figure 1. As^{III} reduces the expression of BRCA1 and ER α . (A) MCF7 cells were cultured for 72 h in control DMEM, or DMEM plus E2 (10 nM) alone or various concentrations of NaAs^{III} as described in the Materials and methods. In (B) MCF7 cells were co-treated for 72 h with E2 plus 2 μ M NaAs^{III} and various concentrations (0.02, 0.2 and 2.0 μ M) of GEN. Bands are representative immunocomplexes for BRCA1 and internal standard GAPDH from two (n=2) separate experiments performed in duplicate. (C) Bars represent the means \pm SEM of ER α mRNA expression (fold-change of E2 Control) from 2 separate experiments (n=2) performed in triplicate. Different letters indicate statistically significant multiple comparison (a>b>c>d) differences (P<0.05). As^{III}, trivalent arsenite; BRCA1, breast cancer 1; ER α , estrogen receptor- α ; E2, 17 β -estradiol; NaAs^{III}, sodium arsenite; GEN, genistein.

prepared for DNA enzymatic digestion. Aliquots of digested chromatin were immunoprecipitated using antibodies against DNMT1 (Abcam Inc, Cambridge, MA, USA) and PolII (Thermo Fisher Scientific). qPCR was performed on aliquots of DNA obtained after the reversal of DNA-protein cross-links and purification through spin-filtration columns. Briefly, PCR amplification reactions were done at a final volume of 25 μ l consisting of the following: 12.5 μ l of SYBR-Green buffer, 1 μ l each forward (5'-CTCCATCCTCTGATTGTACCTTGAT-3') and reverse (5'-CAGGAAGTCTCAGCGAGCTCAC-3') oligonucleotides flanking exon-1a in the *BRCA1* gene (39); 8.5 μ l nuclease free water, and 2 μ l DNA purified from the ChIP assay.

mRNA analyses. Total RNA was purified using RNeasy Mini kit as per the manufacturer's instructions (Qiagen) (38). The concentrations and quality of RNA were verified using the Nanodrop 1000 Spectrophotometer (Thermo Fisher Scientific). Equal amounts of total RNA (500 ng) were transcribed into cDNA using ISCRIPt supermix kit (Bio-Rad Laboratories, Hercules, CA, USA). Next, cDNA aliquots were analyzed by qPCR using the SYBR-Green PCR Reagents kit (Life Technologies/Thermo Fisher Scientific). Briefly, reactions were run at a final volume of 25 μ l consisting of the following master mix: 12.5 μ l of SYBR-Green mix, 1 μ l each of forward and reverse primers, 9.5 μ l nuclease-free water and 1 μ l cDNA. The primer (Sigma-Aldrich) sequences were: *ER α* sense, 5'-CAAGCCCCTCATGATCAA-3' and antisense, 5'-CTGATCATGGAGGGTCAAATCCAC-3'; *BRCA1* sense, 5'-AGTCTCGTGGAGACTTCCTGGA-3' and antisense, 5'-CAATTCAATGTAGACATCCGT-3'; cyclin D1 (*CCND1*) sense, 5'-ACAAACAGATCATCCGCAAACAC-3' and antisense, 5'-TGTTGGGGCTCCTCAGGTTTC-3'; folate receptor 1 (*FOLR1*) sense, 5'-ATTCCTTGGTGCCACTGACC-3' and antisense, 5'-ATAGAACCTCGCCACCTCCT-3'; methyltetrahydrofolate reductase (*MTHFR*) sense, 5'-AAGCCTCTT CTTTGTGCGCA-3' and antisense, 5'-AGGACCCTGGCTT TTCGATG-3'; and control glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*) sense, 5'-ACCCACTCCTCCACCTTT-3' and antisense, 5'-CTCTTGTGCTCTTGCTGGG-3'.

Amplification of *GAPDH* mRNA was used for the normalization of the transcript levels.

Western blot analysis. Western blot analysis was performed as previously described (38). Protein lysates were obtained from cells scraped in triplicates from 6-well plates and using Pierce RIPA buffer (Thermo Fisher Scientific), with 1% proteinase inhibitors. The protein concentration was calculated using a Nanodrop 1000 Spectrophotometer (Thermo Fisher Scientific). Immunoblotting was carried out with antibodies against BRCA1 (cat. no. 9010); GAPDH (cat. no. 2118) (both from Cell Signaling Technology, Beverly, MA, USA); and ER α (cat. no. sc-542) (Santa Cruz Biotechnology, Dallas, TX, USA). Immunocomplexes were detected using enhanced chemiluminescence (GE Healthcare Life Sciences, Little Chalfont, UK). Immunocomplexes for GAPDH were used as an internal control for the normalization of protein expression. Western blot analyses were carried out at least twice for each experiment. The quantification of immunocomplexes was carried out by densitometry performed using Kodak ID Image Analysis Software (Eastman Kodak Company, Rochester, NY, USA).

Mouse mammary xenografts. All *in vivo* mouse xenograft experiments were performed under the #07-029 protocol approved by the University of Arizona Institutional Animal Care and Use Committee approved on 02/22/2016. All procedures were performed in compliance with the standard operating procedures and relevant guidelines of the University of Arizona Animal Care. MCF7 cells (7.5-10 \times 10⁶ cells in 50 μ l of Matrigel resuspension) pre-cultured for 4 weeks in control DMEM/F12 media plus 10% FCS (MCF7 Control) or DMEM/F12 plus 10% FCS with 1 μ M NaAs^{III} (MCFAs^{III}) were injected into the left number-4 mammary fat pad of 4-week-old (19-22 g) ovariectomized (OVX) athymic rTac:NCr-Foxn1 nude female mice (Taconic Biosciences, Rensselaer, NY, USA) implanted with an estradiol pellet (0.72 mg, 60 days release; Innovative Research of America, Sarasota, FL, USA). After 30 days, the mice injected were with MCF7 control or MCF7NaAs^{III} cells were implanted with TAM pellets (5 mg, 60 days release; Innovative Research of America). Mice




Figure 2. Long-term exposure to As^{III} reduces expression of BRCA1 and ER α . MCF7 cells were cultured for various periods of time (4 days to 7 weeks) in control DMEM, or DMEM plus 1 μ M NaAs^{III}. (A) Bars represent the means \pm SEM of *ER α* , *BRCA1* and *CCND1* mRNA expression (fold-change of DMEM Control) from two separate experiments (n=2) performed in triplicate. Asterisk indicates statistically significant differences (P<0.05) compared to the DMEM control. (B-D) Bands are representative immunocomplexes for BRCA1, ER α , CCND1 and internal standard GAPDH from 2 (n=2) separate experiments performed in duplicate. As^{III}, trivalent arsenite; BRCA1, breast cancer 1; ER α , estrogen receptor- α ; NaAs^{III}, sodium arsenite; CCND1, cyclin D1.




Figure 3. Long-term exposure to As^{III} induces the expression of FOLR1. (A) Bars represent the means \pm SEM of *MTHFR*, *FOLR1* and *BRCA1* mRNA expression (fold-change of DMEM Control) from 2 separate experiments (n=2) performed in triplicate. Asterisk indicates statistically significant differences (P<0.05) compared to the DMEM control. (B) Bands are representative immunocomplexes for FOLR1 and internal standard GAPDH from two (n=2) separate experiments performed in duplicate. As^{III}, trivalent arsenite; BRCA1, breast cancer 1; MTHFR, methylenetetrahydrofolate reductase; FOLR1, folate receptor 1.

(10 animals/group \times 4 experimental groups, 40 animals in total) were housed in conventional pathogen-free cages under a 12 h light/12 h dark cycle, at 20–22°C, and 50–55% humidity with free access to Teklad Global Rodent Diet (Harlan Laboratories, Madison, WI, USA) and tap water. The animals were sacrificed at 60 days after the start of TAM treatment. Tumor growth was measured once/week with a caliper until there were visible signs of tumor growth, then twice/week

until the end of the study. Tumor volume was estimated using the following formula: [(width)² \times length]/2]. Tumor tissue was snap-frozen in liquid nitrogen and stored at -80°C for further analysis.

Statistical analysis. Data were analyzed by ANOVA as previously described (38). Post-hoc multiple comparisons among all means were conducted using Tukey's Test after main effects and interactions were found to be significant at P \leq 0.05. Data are presented as the means \pm SEM and statistical differences highlighted with different letters for multiple comparisons (a>b>c, etc.) or asterisks when compared to the control.

Results

NaAs^{III} reduces the expression of BRCA1 via CpG hypermethylation in ER α -positive breast cancer cells. Previously (38–40), we reported that the expression of BRCA1 was stimulated by E2 in ER-positive MCF7 breast cancer cells (38). In this study, using western blot analysis (Fig. 1A), we observed that E2-induced BRCA1 expression was antagonized by NaAs^{III}, starting at the 1 μ M concentration, and to a larger degree upon co-treatment with higher doses of NaAs^{III} (2 to 8 μ M). As a control, we co-treated MCF7 cells with NaAs^{III} (2 μ M) plus various doses (0.02, 0.2 and 2.0 μ M) of the isoflavone GEN, which was found in our previous study to induce BRCA1 expression (38). Co-treatment with 0.2 and 2 μ M GEN reversed the repressive effects of NaAs^{III} on BRCA1 expression (Fig. 1B). Based on the information that *BRCA1* transcription is regulated by the ER α (40), changes in the expression of *ER α* mRNA were analyzed by qPCR in MCF7 cells treated for 72 h with various doses of NaAs^{III}. Compared to the E2 control, treatment with 1 μ M NaAs^{III} decreased *ER α* mRNA expression by \sim 15%, which was further decreased (55–70%) by higher concentrations (2 and 4 μ M) of NaAs^{III} (Fig. 1C). Based on these dose-response




Figure 4. As^{III} induces *BRCA1* CpG methylation. MCF7 cells were cultured in control DMEM or DMEM plus 1 μ M NaAs^{III}. Bars represent the means \pm SEM of fold-change of DMEM Control for (A) *BRCA1* CpG methylation (4 days to 10 weeks) and (B) PolII and DNMT1 recruitment (6 days) by ChIP assay at the *BRCA1* gene from 2 separate experiments (n=2) performed in triplicate. (A) Asterisk or (B) different letters indicates statistically significant multiple comparison (a>b>c>d) differences (P<0.05) compared to the DMEM control. As^{III}, trivalent arsenite; *BRCA1*, breast cancer 1; NaAs^{III}, sodium arsenite; PolII, polymerase II.

results, we examined the long-term effects of exposure to 1 μ M NaAs^{III}, which approximates levels of As^{III} measured in drinking water of populations residing in the US (41) and other geographical regions (42-44). MCF7 cells were cultured for various periods of time (4 days to 7 weeks) either as control DMEM cells or in the presence of 1 μ M NaAs^{III}, which reduced the expression of *ER α* and *BRCA1* mRNA (Fig. 2A). In parallel, the expression of *CCND1* was reduced by \sim 25% within 4 days post-treatment with NaAs^{III}, whereas the *CCND1* levels were enhanced by longer exposure to NaAs^{III}. Western blot analysis confirmed that long-term (5 weeks) exposure to NaAs^{III} had repressive effects on E2-induced *BRCA1* (Fig. 2B) and *ER α* (Fig. 2C), but induced the expression of *CCND1*.

It has previously been documented (45) that As^{III} treatment decreases the expression of *MTHFR*, an enzyme involved in one-carbon metabolism. Analysis of *MTHFR* expression by RT-qPCR (Fig. 3A) showed that 1 to 6 weeks exposure of MCF7 cells to 1 μ M NaAs^{III} reduced markedly (\sim 50%) *MTHFR* mRNA. The treatment with NaAs^{III} had a biphasic effect on expression of *FOLR1* mRNA, which was reduced at 1 and 3 weeks, but induced at 6 weeks, of exposure. *FOLR1* participates in cellular uptake of 5-methyltetrahydrofolate into cells, and its overexpression has been linked to poor prognosis in particular in triple-negative breast cancers (TNBC) (46). As an additional control, we confirmed the repressive effects on *BRCA1* mRNA expression by treatment of the MCF7 cells with NaAs^{III} by RT-qPCR. As another control, we also examined the expression of *FOLR1* protein and found that exposure to NaAs^{III} reduced its expression within 3 days, although it had a stimulatory effect long-term (19 weeks) (Fig. 3B).

One mechanism through which NaAs^{III} may lower *BRCA1* expression is epigenetic silencing involving DNA methylation. The analysis of bisulfonated genomic DNA prepared from the MCF7 cells revealed that exposure to 1 μ M NaAs^{III} from 4 days to 10 weeks brought about an increase (2.5- to 5-fold) in *BRCA1* CpG methylation (Fig. 4A), which was associated at 6 days

post-treatment with a reduction in the recruitment of PolII to the *BRCA1* promoter and increased occupancy by DNMT1 (Fig. 4B). These results suggested that the NaAs^{III}-dependent downregulation of *BRCA1* was associated with the reduced transcription and recruitment of DNA-modifying enzymes (i.e., DNMT1) to the *BRCA1* gene.

NaAs^{III} disrupts the response to TAM in MCF7 cells in culture and in mouse mammary tumor xenografts. The observed reduction in *ER α* expression depicted in Figs. 1 and 2 raised the question as to whether NaAs^{III} exposure influences E2-induced cell proliferation and response to TAM. The results presented in Fig. 5 indicated that treatment of the MCF7 cells with TAM for 72 h reduced E2-induced cell growth. Conversely, in the MCF7 cells pre-treated for 6 weeks with 1 μ M NaAs^{III}, treatment with TAM increased cell proliferation (Fig. 5A). The results of western blot analysis indicated that pre-treatment with NaAs^{III} for 6 weeks antagonized E2-induced *BRCA1* expression, while it reduced *ER α* expression, a known target for TAM (Fig. 5B). The analysis of cell cycle distribution by flow cytometry revealed that a larger percentage of cells co-treated for 6 weeks with NaAs^{III} plus TAM or E2 plus TAM were positioned in the S-phase of the cell cycle compared to the control MCF7 cells (Fig. 5C). These cumulative results suggested that long-term exposure to environmentally relevant doses (1 μ M) of NaAs^{III} increased the resistance of MCF7 cells to TAM through the downregulation of *ER α* .

To further investigate the influence of NaAs^{III} exposure on tumor development, we injected control MCF7 cells or MCF7 cells pre-treated with 1 μ M NaAs^{III} for 4 weeks (MCF7 NaAs^{III}) into the cleared mammary fat pad of 4-week-old OVX athymic rTac:NCr-Foxn1 nude female mice also implanted with an E2 pellet. We then monitored tumor growth for 24 days and noted a higher tumor volume for mice injected with MCF7 NaAs^{III} compared to mice xenografted with control MCF7 cells (Fig. 6A). Subsequently, the xenografted mice were




Figure 5. As^{III} antagonizes the TAM-dependent inhibition of proliferation. MCF7 cells and MCF7 cells pre-treated for 6 weeks in the presence of 1 μ M NaAs^{III} (MCF7NaAs^{III}) were cultured for 72 h in control DMEM, or DMEM plus E2 (10 nM), TAM (1 μ M), or their combination. (A) Bars represent the means \pm SEM of quantitation (fold-change of DMEM Control) of proliferation determined by MTT assay from 2 separate experiments (n=2) with 5 replicates. (B) Bands are representative immunocomplexes for BRCA-1, ER α and internal standard GAPDH from 2 (n=2) separate experiments performed in duplicate. (C) Bars represent the means \pm SEM of percentage cells in S-phase measured by flow cytometry from two separate experiments (n=2) with 5 replicates. In (A) and (C) different letters represent statistically significant multiple comparison (a>b>c, etc.) differences (P<0.05). As^{III}, trivalent arsenite; BRCA1, breast cancer 1; NaAs^{III}, sodium arsenite; TAM, tamoxifen; E2, 17 β -estradiol.




Figure 6. As^{III} promotes growth of MCF7 cell mammary xenografts and antagonizes the anti-proliferative effects of TAM. MCF7 and MCF7 cells pre-cultured for 4 weeks in DMEM plus 1 μ M NaAs^{III} (MCF7NaAs^{III}) were xenografted into the mammary fat pad of OVX nude mice implanted with E2 pellets as described in the Materials and methods. Tumors were allowed to grow for 24 days, after which mice were implanted with TAM pellets. (A) Tumor burden (mm³) was measured up to 24 days post-xenograft. (B) Tumor burden (mm³ fold-change of TAM/Control) was measured at 45 days after the implantation of TAM pellets. Bars are the means \pm SEM from 5 animals/group from 2 separate experiments (n=10). Asterisks represent statistically significant differences (P<0.05) compared to MCF7 control xenografts. TAM, tamoxifen; NaAs^{III}, sodium arsenite.

implanted with a TAM pellet and tumors were allowed to grow for an additional 45 days. Mammary tumors that originated from xenografted MCF7 NaAs^{III} cells were more refractory (~40%) to TAM treatment compared with tumors that developed from control MCF7 cells (Fig. 6B). The resilience of MCF7 NaAs^{III} tumors to TAM was coupled with the reduced expression of *BRCA1* and *ER α* mRNA (Fig. 7A), and increased CpG methylation of the respective genes (i.e., *BRCA1* and *ESR1*) (Fig. 7B). As a control, we measured the expression of *FOLR1* mRNA (Fig. 8A) and *FOLR1* protein (Fig. 8B), which were increased (~1.0-fold) in mammary tumors from xenografted MCF7 NaAs^{III} cells compared to tumors that developed from control MCF7 cells. Taken together, the results of the tumor xenograft experiments indicated that exposure to NaAs^{III}

conferred the resistance of mammary tumors to TAM and that this resilience was associated with the hypermethylation of *BRCA1* and *ESR1*, the reduced expression of *BRCA1* and *ER α* , and increased levels of *FOLR1* mRNA and tumor burden.

Discussion

The loss of *ER α* expression has been linked to a poor response to endocrine therapy (16-18). Drinking water contaminated with arsenic has been linked to the disruption of *ER α* signaling (19) and arsenic exposure has been shown to contribute to genomic instability through the disruption of *BRCA1*-regulated DNA repair (20). Arsenic may accelerate cancer growth (24) and confer a steroid receptor-independent phenotype (29). These




Figure 7. As^{III} induces *BRCA1* and *ESR1* CpG methylation in MCF7 cell mammary tumor xenografts. Bars are from 5 animals/group from 2 separate experiments (n=10) and represent the means (fold-change of MCF7 Control xenograft) ± SEM for (A) *BRCA1* and *ERα* mRNA expression; (B) *BRCA1* and *ESR1* CpG methylation. Different letters represent statistically significant multiple comparison (a>b>c) differences (P<0.05). As^{III}, trivalent arsenite; *BRCA1*, breast cancer 1; *ESR1*, estrogen receptor 1; *ERα*, estrogen receptor-α.




Figure 8. As^{III} induces expression of FOLR1 in MCF7 cell mammary tumor xenografts. (A) *FOLR1* mRNA expression in MCF7 and MCF7NaAs^{III} cell mammary tumor xenografts. Bars are from 5 animals/group from two separate experiments (n=10) and represent means (fold-change of MCF7 Control xenograft) ± SEM. Different letters represent statistically significant multiple comparison (a>b) differences (P<0.05). (B) Bands are representative immunocomplexes for FOLR1 and internal standard GAPDH from 2 (n=2) separate experiments performed in duplicate. As^{III}, trivalent arsenite; *BRCA1*, breast cancer 1; FOLR1, folate receptor 1.

cumulative observations suggest arsenic exposure may interfere with endocrine regulation and prompted our investigation into whether or not As^{III} contributes to resistance to TAM therapy through the silencing of *BRCA1* and *ESR1*. In this study, we first examined the *in vitro* effects of NaAs^{III} in ERα-positive breast cancer cells and found that acute (within 4 days) and long-term (10 days to 7 weeks) exposure to environmentally relevant doses of As^{III} reduced *BRCA1* expression. Furthermore, NaAs^{III} compromised ERα expression and the *in vitro* response of MCF7 cells to treatment with TAM. In normal breast epithelial cells, the *BRCA1* and *ESR1* (encoding for ERα) genes are regulated through a positive feedback loop in which ERα induces expression of *BRCA1* in the presence of E2 (40). In turn, *BRCA1* transcriptionally activates the *ESR1* gene (47). This crosstalk between *BRCA1* and ERα is thought to favor DNA repair controlled by *BRCA1* before cells progress through division under the proliferative pressure of estrogens. Conversely, in *BRCA1* mutation and sporadic breast tumors,

the reduced expression of *BRCA1*, also termed 'BRCAness', is usually associated with the reduced expression of ERα and resistance to TAM (48). Our cell culture data suggested that exposure to NaAs^{III} may compromise *BRCA1* expression and confer resistance to antagonists of the ERα such as TAM. The results of this study are in agreement with those of a previous study (49) showing that environmentally relevant doses of NaAs^{III} (~1-5 μM) reduced the expression of the ERα.

A mechanism that may contribute to the NaAs^{III}-dependent loss of *BRCA1* is epigenetic silencing via CpG methylation, which has been documented in sporadic breast tumors, particularly in those that are more invasive (i.e., TNBC) compared to lobulo-alveolar breast cancers (50). In this study, we documented that in MCF7 cells both the short- (4 days) and long- (10 days to 10 weeks) term *in vitro* exposure to NaAs^{III} induced *BRCA1* CpG methylation was associated with the increased recruitment of DNMT1 and the loss of PolII at the *BRCA1* gene. These observations are in accordance with those

of a previous study reporting promoter hypermethylation and silencing of other DNA repair (*MLH1* and *MSH2*) genes in arsenic-exposed populations (51). The reprogramming of DNA methylation elicited by NaAs^{III} has been previously linked to increased growth rate (52). In keeping with these earlier reports, in this study, we noted that MCF7 treated for 6 weeks with NaAs^{III} displayed increased proliferative capacity and were refractory to TAM.

The injection of NaAs^{III}-preconditioned MCF7 cells into the mammary fat pad of nude mice provided *in vivo* evidence that the prior exposure to NaAs^{III} may alter the behavior of ER α -positive breast cancer cells. Xenografted MCF7NaAs^{III} cells produced a larger tumor volume compared to control MCF7 cells and were more refractory to treatment with TAM. We attributed this resilience of MCF7NaAs^{III} to TAM, at least in part, to the reduced expression of ER α associated with the CpG hypermethylation of *ESR1*. The reduced expression of ER α in MCF7NaAs^{III} tumors was paralleled by the lower expression and hypermethylation of *BRCA1*, further supporting the hypothesis that exposure to NaAs^{III} may contribute to breast tumorigenesis by hampering DNA repair capacity controlled by *BRCA1* and altering the crosstalk between *BRCA1* and ER α .

In agreement with previous findings (45), we noted that the expression of *MTHFR* in MCF7 cells treated *in vitro* with NaAs^{III} was markedly downregulated. Thus, exposure to inorganic arsenic may deplete the pool of methyl groups and interfere with folate metabolism with consequences on DNA synthesis and repair. The reduced expression of *MTHFR* has been previously associated with breast cancer development (53). Conversely, in this study, we noted in MCF7 cells in culture that exposure to NaAs^{III} had a biphasic effect on the expression of FOLR1, a membrane-bound protein involved in transport of folate into cells. Short-term exposure to NaAs^{III} reduced FOLR1 expression, whereas a stimulatory effect on FOLR1 levels was observed after long-term exposure. The upregulation of FOLR1 was confirmed in mammary tumors that developed from xenografted MCF7NaAs^{III} cells. The upregulation of FOLR1 has been interpreted as an adaptive response triggered by cellular depletion of methyl groups by metabolism of NaAs^{III} (45). Moreover, recent studies reported that the increased expression of FOLR1 was associated with a higher risk of recurrence in patients with TNBC (54), which were significantly enriched in FOLR1 compared to ER α - and human epidermal growth factor receptor 2-positive breast tumors (46). Whereas it remains unknown whether NaAs^{III} affects expression of *MTHFR* and FOLR1 through epigenetic mechanisms, a possible translational implication of our data is that breast cancer patients exposed to NaAs^{III} and undergoing treatment with TAM may benefit from combination therapy with anti-FOLR1 agents (54).

Taken together, the data of the present study provide novel *in vitro* and mammary tumor xenograft evidence that exposure to inorganic trivalent arsenic, such as NaAs^{III} may increase resistance to endocrine therapy based on TAM through reduction in *BRCA1* and ER α expression. Future studies with ER α -positive breast cancer patients residing in geographical regions at high risk of exposure to As^{III} are warranted to investigate whether the dysregulation of CpG hypermethylation of *BRCA1* and *ESR1* causes persistent

genomic instability (55), and variations in efficacy of therapies based on antagonists of the ER α . As DNA methylation changes are potentially reversible, they may offer a novel target for combination therapies of ER-positive breast tumors with epigenetic drugs.

Acknowledgements

The authors wish to acknowledge the support of The Experimental Mouse Shared Resource Core of the University of Arizona Cancer Center.

Funding

This study was supported by a Pilot Project grant from the National Cancer Institute of the National Institutes of Health under the award for the Partnership of Native American Cancer Prevention U54CA143924 (UACC); Cancer Biology Training Grant T32CA009213; and Cancer Center Support Grant P30CA023074.

Availability of data and materials

All data generated during this study are included in this published article.

Authors' contributions

OIS and DFR conceived the study and drafted the manuscript. MGD contributed to laboratory experiments, data analysis, and writing of the manuscript. OIS conducted cellular and molecular measurements with cell lines and tumor xenografts. BS and GDPM contributed to designing and performing the xenograft experiments and review of data. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

All mouse xenograft experiments were performed under the #07-029 protocol approved by the University of Arizona Institutional Animal Care and Use Committee approved on 02/22/2016. All procedures were performed in compliance with the standard operating procedures and relevant guidelines of the University of Arizona Animal Care.

Patient consent for publication

Not applicable

Competing interests

The authors declare they have no competing interests.

References

1. Ayotte JD, Belaval M, Olson SA, Burow KR, Flanagan SM, Hinkle SR and Lindsey BD: Factors affecting temporal variability of arsenic in groundwater used for drinking water supply in the United States. *Sci Total Environ* 505: 1370-1379, 2015.
2. Sorg TJ, Chen AS and Wang L: Arsenic species in drinking water wells in the USA with high arsenic concentrations. *Water Res* 48: 156-169, 2014.

3. Agusa T, Trang PT, Lan VM, Anh DH, Tanabe S, Viet PH and Berg M: Human exposure to arsenic from drinking water in Vietnam. *Sci Total Environ* 488-489: 562-569, 2014.
4. Dummer TJ, Yu ZM, Nauta L, Murimboh JD and Parker L: Geostatistical modelling of arsenic in drinking water wells and related toenail arsenic concentrations across Nova Scotia, Canada. *Sci Total Environ* 505: 1248-1258, 2015.
5. George CM, Sima L, Arias MH, Mihalic J, Cabrera LZ, Danz D, Checkley W and Gilman RH: Arsenic exposure in drinking water: An unrecognized health threat in Peru. *Bull World Health Organ* 92: 565-572, 2014.
6. García-Esquinas E, Pollán M, Umans JG, Francesconi KA, Goessler W, Guallar E, Howard B, Farley J, Best LG and Navas-Acien A: Arsenic exposure and cancer mortality in a US-based prospective cohort: The strong heart study. *Cancer Epidemiol Biomarkers Prev* 22: 1944-1953, 2013.
7. Saint-Jacques N, Parker L, Brown P and Dummer TJ: Arsenic in drinking water and urinary tract cancers: a systematic review of 30 years of epidemiological evidence. *Environ Health* 13: 44, 2014.
8. Gentry PR, Clewell HJ III, Greene TB, Franzen AC and Yager JW: The impact of recent advances in research on arsenic cancer risk assessment. *Regul Toxicol Pharmacol* 69: 91-104, 2014.
9. Stoica A, Pentecost E and Martin MB: Effects of arsenite on estrogen receptor-alpha expression and activity in MCF-7 breast cancer cells. *Endocrinology* 141: 3595-3602, 2000.
10. Ren X, McHale CM, Skibola CF, Smith AH, Smith MT and Zhang L: An emerging role for epigenetic dysregulation in arsenic toxicity and carcinogenesis. *Environ Health Perspect* 119: 11-19, 2011.
11. Gentry PR, McDonald TB, Sullivan DE, Shipp AM, Yager JW and Clewell HJ III: Analysis of genomic dose-response information on arsenic to inform key events in a mode of action for carcinogenicity. *Environ Mol Mutagen* 51: 1-14, 2010.
12. Kijima I, Itoh T and Chen S: Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen. *J Steroid Biochem Mol Biol* 97: 360-368, 2005.
13. Khanjani N, Jafarnejad AB and Tavakkoli L: Arsenic and breast cancer: A systematic review of epidemiologic studies. *Rev Environ Health* 32: 267-277, 2017.
14. Musgrove EA and Sutherland RL: Biological determinants of endocrine resistance in breast cancer. *Nat Rev Cancer* 9: 631-643, 2009.
15. Schiff R, Massarweh S, Shou J and Osborne CK: Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. *Clin Cancer Res* 9 (1 Pt 2): 447S-454S, 2003.
16. Johnston SR, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR and Dowsett M: Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. *Cancer Res* 55: 3331-3338, 1995.
17. Kuukasjärvi T, Kononen J, Helin H, Holli K and Isola J: Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. *J Clin Oncol* 14: 2584-2589, 1996.
18. Osborne CK and Schiff R: Mechanisms of endocrine resistance in breast cancer. *Annu Rev Med* 62: 233-247, 2011.
19. Muñoz A, Chervona Y, Hall M, Kluz T, Gamble MV and Costa M: Sex-specific patterns and deregulation of endocrine pathways in the gene expression profiles of Bangladeshi adults exposed to arsenic contaminated drinking water. *Toxicol Appl Pharmacol* 284: 330-338, 2015.
20. Peremartí J, Ramos F, Marcos R and Hernández A: Arsenic exposure disrupts the normal function of the FA/BRCA repair pathway. *Toxicol Sci* 142: 93-104, 2014.
21. Parodi DA, Greenfield M, Evans C, Chichura A, Alpaugh A, Williams J and Martin MB: Alteration of mammary gland development and gene expression by in utero exposure to arsenic. *Reprod Toxicol* 54: 66-75, 2015.
22. Tokar EJ, Diwan BA, Ward JM, Delker DA and Waalkes MP: Carcinogenic effects of 'whole-life' exposure to inorganic arsenic in CD1 mice. *Toxicol Sci* 119: 73-83, 2011.
23. Waalkes MP, Liu J, Ward JM and Diwan BA: Animal models for arsenic carcinogenesis: Inorganic arsenic is a transplacental carcinogen in mice. *Toxicol Appl Pharmacol* 198: 377-384, 2004.
24. Schrauzer GN, White DA, McGinness JE, Schneider CJ and Bell LJ: Arsenic and cancer: Effects of joint administration of arsenite and selenite on the genesis of mammary adenocarcinoma in inbred female C3H/St mice. *Bioinorg Chem* 9: 245-253, 1978.
25. Liu Y, Hock JM, Sullivan C, Fang G, Cox AJ, Davis KT, Davis BH and Li X: Activation of the p38 MAPK/Akt/ERK1/2 signal pathways is required for the protein stabilization of CDC6 and cyclin D1 in low-dose arsenite-induced cell proliferation. *J Cell Biochem* 111: 1546-1555, 2010.
26. Xu Y, Tokar EJ and Waalkes MP: Arsenic-induced cancer cell phenotype in human breast epithelia is estrogen receptor-independent but involves aromatase activation. *Arch Toxicol* 88: 263-274, 2014.
27. Tong D, Ortega J, Kim C, Huang J, Gu L and Li GM: Arsenic Inhibits DNA Mismatch Repair by Promoting EGFR Expression and PCNA Phosphorylation. *J Biol Chem* 290: 14536-14541, 2015.
28. Bhattacharjee P, Banerjee M and Giri AK: Role of genomic instability in arsenic-induced carcinogenicity. A review. *Environ Int* 53: 29-40, 2013.
29. Benbrahim-Tallaa L, Webber MM and Waalkes MP: Acquisition of androgen independence by human prostate epithelial cells during arsenic-induced malignant transformation. *Environ Health Perspect* 113: 1134-1139, 2005.
30. Baylin SB and Jones PA: A decade of exploring the cancer epigenome - biological and translational implications. *Nat Rev Cancer* 11: 726-734, 2011.
31. Cardenas A, Houseman EA, Baccarelli AA, Quamruzzaman Q, Rahman M, Mostofa G, Wright RO, Christiani DC and Kile ML: In utero arsenic exposure and epigenome-wide associations in placenta, umbilical artery, and human umbilical vein endothelial cells. *Epigenetics* 10: 1054-1063, 2015.
32. Chou WC, Chung YT, Chen HY, Wang CJ, Ying TH, Chuang CY, Tseng YC and Wang SL: Maternal arsenic exposure and DNA damage biomarkers, and the associations with birth outcomes in a general population from Taiwan. *PLoS One* 9: e86398, 2014.
33. Cui X, Wakai T, Shirai Y, Hatakeyama K and Hirano S: Chronic oral exposure to inorganic arsenate interferes with methylation status of p16INK4a and RASSF1A and induces lung cancer in A/J mice. *Toxicol Sci* 91: 372-381, 2006.
34. Ramirez T, Brocher J, Stopper H and Hock R: Sodium arsenite modulates histone acetylation, histone deacetylase activity and HMGN protein dynamics in human cells. *Chromosoma* 117: 147-157, 2008.
35. Lu G, Xu H, Chang D, Wu Z, Yao X, Zhang S, Li Z, Bai J, Cai Q and Zhang W: Arsenic exposure is associated with DNA hypermethylation of the tumor suppressor gene p16. *J Occup Med Toxicol* 9: 42, 2014.
36. Zhang TC, Schmitt MT and Mumford JL: Effects of arsenic on telomerase and telomeres in relation to cell proliferation and apoptosis in human keratinocytes and leukemia cells in vitro. *Carcinogenesis* 24: 1811-1817, 2003.
37. Jiang R, Li Y, Zhang A, Wang B, Xu Y, Xu W, Zhao Y, Luo F and Liu Q: The acquisition of cancer stem cell-like properties and neoplastic transformation of human keratinocytes induced by arsenite involves epigenetic silencing of *let-7c* via Ras/NF- κ B. *Toxicol Lett* 227: 91-98, 2014.
38. Romagnolo DF, Donovan MG, Papoutsis AJ, Doetschman TC and Selmin OI: Genistein prevents BRCA1 CpG methylation and proliferation in human breast cancer cells with activated aromatic hydrocarbon receptor. *Curr Dev Nutr* 1: e000562, 2017.
39. Papoutsis AJ, Borg JL, Selmin OI and Romagnolo DF: BRCA-1 promoter hypermethylation and silencing induced by the aromatic hydrocarbon receptor-ligand TCDD are prevented by resveratrol in MCF-7 cells. *J Nutr Biochem* 23: 1324-1332, 2012.
40. Jeffy BD, Hockings JK, Kemp MQ, Morgan SS, Hager JA, Beliakov J, Whitesell LJ, Bowden GT and Romagnolo DF: An estrogen receptor-alpha/p300 complex activates the BRCA-1 promoter at an AP-1 site that binds Jun/Fos transcription factors: Repressive effects of p53 on BRCA-1 transcription. *Neoplasia* 7: 873-882, 2005.
41. Lothrop N, Wilkinson ST, Verhoughstraete M, Sugeng A, Loh MM, Klimecki W and Beamer PI: Home Water Treatment Habits and Effectiveness in a Rural Arizona Community. *Water* 7: 1217-1231, 2015.
42. Hough RL, Fletcher T, Leonardi GS, Goessler W, Gnagnarella P, Clemens F, Gurzau E, Koppova K, Rudnai P, Kumar R, *et al*: Lifetime exposure to arsenic in residential drinking water in Central Europe. *Int Arch Occup Environ Health* 83: 471-481, 2010.
43. Kumar A, Adak P, Gurian PL and Lockwood JR: Arsenic exposure in US public and domestic drinking water supplies: A comparative risk assessment. *J Expo Sci Environ Epidemiol* 20: 245-254, 2010.

44. Raessler M: The Arsenic Contamination of Drinking and Groundwaters in Bangladesh: Featuring Biogeochemical Aspects and Implications on Public Health. *Arch Environ Contam Toxicol* 75: 1-7, 2018.
45. Ruiz-Ramos R, López-Carrillo L, Albores A, Hernández-Ramírez RU and Cebrian ME: Sodium arsenite alters cell cycle and MTHFR, MT1/2, and c-Myc protein levels in MCF-7 cells. *Toxicol Appl Pharmacol* 241: 269-274, 2009.
46. Necela BM, Crozier JA, Andorfer CA, Lewis-Tuffin L, Kachergus JM, Geiger XJ, Kalari KR, Serie DJ, Sun Z, Moreno-Aspitia A, *et al*: Correction: Folate receptor- α (FOLR1) expression and function in triple negative tumors. *PLoS One* 10: e0127133, 2015.
47. Hosey AM, Gorski JJ, Murray MM, Quinn JE, Chung WY, Stewart GE, James CR, Farragher SM, Mulligan JM, Scott AN, *et al*: Molecular basis for estrogen receptor alpha deficiency in *BRCA1*-linked breast cancer. *J Natl Cancer Inst* 99: 1683-1694, 2007.
48. Lips EH, Mulder L, Oonk A, van der Kolk LE, Hogervorst FB, Imholz AL, Wesseling J, Rodenhuis S and Nederlof PM: Triple-negative breast cancer: BRCAness and concordance of clinical features with *BRCA1*-mutation carriers. *Br J Cancer* 108: 2172-2177, 2013.
49. Nakareangrit W, Thiantanawat A, Visitnonthachai D, Watcharasit P and Satayavivad J: Sodium arsenite inhibited genomic estrogen signaling but induced pER α (Ser118) via MAPK pathway in breast cancer cells. *Environ Toxicol* 31: 1133-1146, 2016.
50. Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG and Eyfjord JE: Epigenetic silencing and deletion of the *BRCA1* gene in sporadic breast cancer. *Breast Cancer Res* 8: R38, 2006.
51. Bhattacharjee P, Sanyal T, Bhattacharjee S and Bhattacharjee P: Epigenetic alteration of mismatch repair genes in the population chronically exposed to arsenic in West Bengal, India. *Environ Res* 163: 289-296, 2018.
52. Riedmann C, Ma Y, Melikishvili M, Godfrey SG, Zhang Z, Chen KC, Rouchka EC and Fondufe-Mittendorf YN: Inorganic Arsenic-induced cellular transformation is coupled with genome wide changes in chromatin structure, transcriptome and splicing patterns. *BMC Genomics* 16: 212, 2015.
53. Zara-Lopes T, Gimenez-Martins AP, Nascimento-Filho CH, Castanhole-Nunes MM, Galbiatti-Dias AL, Padovani-Júnior JA, Maniglia JV, Francisco JL, Pavarino EC and Goloni-Bertollo EM: Role of MTHFR C677T and MTR A2756G polymorphisms in thyroid and breast cancer development. *Genet Mol Res* 15: gmr8222, 2016.
54. Ginter PS, McIntire PJ, Cui X, Irshaid L, Liu Y, Chen Z and Shin SJ: Folate receptor alpha expression is associated with increased risk of recurrence in triple-negative breast cancer. *Clin Breast Cancer* 17: 544-549, 2017.
55. Mauro M, Caradonna F and Klein CB: Dysregulation of DNA methylation induced by past arsenic treatment causes persistent genomic instability in mammalian cells. *Environ Mol Mutagen* 57: 137-150, 2016.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.